HENDERSON, Nev., June 12, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 11th, 2025
DATE: June 11th
TIME: 1:00 PM ET
LINK: REGISTER HERE
Available for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue.
- NIKA’s partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025.
- On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here.
- On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue.
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward- looking statements.” These forward-looking statements generally are identified by the words “believes,” “expects,” “anticipates,”” estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
Nika Pharmaceuticals, Inc.
Name Clifford P. Redekop
Title Corporate Secretary
Phone (702) 326-3615
Email cliffredekop@gmail.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
